Involvement of Akt and mTOR in chemotherapeutic- and hormonal-based drug resistance and response to radiation in breast cancer cells
Linda S. Steelman(East Carolina University), James A. McCubrey(East Carolina University), Stephen L. Abrams(East Carolina University), Massimo Libra(University of Catania), Lucio Cocco(University of Bologna), William H. Chappell(University of North Carolina at Chapel Hill), Alberto M. Martelli(University of Bologna), Patrick M. Navolanic(East Carolina University), Л. Б. Дробот(Palladin Institute of Biochemistry), Ellis W.T. Wong(Greenville College), Ferdinando Nicoletti(University of Catania), Richard A. Franklin(Kamineni Institute of Dental Sciences), Franca Stivala(University of Catania)
Cited by 91
Related Papers
Natural products in drug discovery: advances and opportunities
|Nature Reviews Drug Discovery|2021|5.2k
Evolution of Cancer Pharmacological Treatments at the Turn of the Third Millennium
|Frontiers in Pharmacology|2018|878
Ras/Raf/MEK/ERK and PI3K/PTEN/Akt/mTOR Inhibitors: Rationale and Importance to Inhibiting These Pathways in Human Health
|Oncotarget|2011|579
GSK-3 as potential target for therapeutic intervention in cancer
|Oncotarget|2014|508